🇺🇸 FDA
Pipeline program

Topical roflumilast 0.3% foam

2020-527

Phase 2 small_molecule active

Quick answer

Topical roflumilast 0.3% foam for Hidradenitis Suppurativa is a Phase 2 program (small_molecule) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcutis Biotherapeutics
Indication
Hidradenitis Suppurativa
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials